1. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC et al.. (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
J Med Chem, 50 (4): 641-62.
[PMID:17256834]
2. Diebold RB, Gero TW, Grover P, Huang S, Ioannidis S, Ogoe CA, Saeh JC. (2016) Chemical compounds.
Patent number: US9248140B2. Assignee: AstraZeneca AB. Priority date: 06/08/2010. Publication date: 02/02/2016.
3. Hopkins J, Tsuruda P, Chapman C, Sweigard H, Poon Y, Marquess D, David N, Dananberd J, Laberg RM. (2019) Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells.
Patent number: WO2019033119A1. Assignee: Unity Biotechnology, Inc., Buck Institute For Research On Aging. Priority date: 13/08/2018. Publication date: 14/02/2019.
4. Le Wang, George A. Doherty, Andrew S. Judd*, Zhi-Fu Tao, T. Matthew Hansen, Robin R. Frey, Xiaohong Song, Milan Bruncko, Aaron R. Kunzer, Xilu Wang, Michael D. Wendt, John A. Flygare, Nathaniel D. Catron, Russell A. Judge, Chang H. Park, Shashank Shekhar, Darren C. Phillips, Paul Nimmer, Morey L. Smith, Stephen K. Tahir, Yu Xiao, John Xue John Xue AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States More by John Xue , Haichao Zhang, Phuong N. Le, Michael J. Mitten, Erwin R. Boghaert, Wenqing Gao, Peter Kovar, Edna F. Choo, Dolores Diaz, Wayne J. Fairbrother, Steven W. Elmore, Deepak Sampath, Joel D. Leverson, and Andrew James Souers. (2020) Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.
ACS Med Chem Lett, [Epub ahead of print].
DOI: 10.1021/acsmedchemlett.9b00568
5. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
Cell Death Differ, 14 (9): 1711-3.
[PMID:17572662]
6. Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J et al.. (2020) A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Oncol Res, 28 (4): 331-344.
[PMID:32093809]
7. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X et al.. (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
J Med Chem, 51 (21): 6902-15.
[PMID:18841882]
8. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al.. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med, 19 (2): 202-8.
[PMID:23291630]
9. Wan Y, Dai N, Tang Z, Fang H. (2018) Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Eur J Med Chem, 146: 471-482.
[PMID:29407973]